Sign in

Bradley Harris

@bradleyomics.bsky.social
92 followers 124 following 19 posts

Postdoc @sangerinstitute.bsky.social | Lover of all things single-cell ‘omic, common complex disease and genetics. Anderson lab - andersonlab.info

PostsRepliesMedia
Reposted by Bradley Harris
Wellcome Sanger Institute @sangerinstitute.bsky.social · 27/08/2025
Scientists have uncovered hidden genetic drivers of conditions like IBD by stimulating immune cells. 🔬 The findings have resulted in a dataset called MacroMap, which offers insight into why some people are vulnerable to certain conditions. sanger.ac.uk/news_item/ac...
sanger.ac.uk
Activated immune cells reveal hidden drivers of autoimmune diseases
A new resource, MacroMap, provides a rich dataset that researchers can use to explore genetic mechanisms behind complex diseases.
1167
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
...clinical collaborators (Tim Raine and @gastrogrj.bsky.social ) and donors and their families! 17/
000
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
Huge thanks to the many members of the @carlanderson.bsky.social team who drove this work (past and present), our funders ( @opentargets.org @crohnscolitisfdn.bsky.social @wellcometrust.bsky.social), @sangerinstitute.bsky.social, ...
https://opentargets.org‬
110
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
If you think this is the coolest thing ever (like I do) then good news 🥳 we are hiring! So do get in touch with myself or @anderson_carl if you’re interested in using genetics and population scale, longitudinal scRNAseq to understand common complex diseases! andersonlab.info 16/
andersonlab.info
Anderson's Lab - WTSI
110
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
🍊The really juicy biology, including deep dives into specific hits and what this could mean for drug development, is summarised by @Tobionformatics here 💊. There’s some very interesting and surprising findings, and even more in the paper - so do check it out! 15/ bsky.app/profile/tobi...
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
These effects can therefore only be captured by using scRNAseq. However, even at this scale, there are many cell-types for which we are relatively underpowered. Continued high resolution eQTL mapping in ever larger datasets will likely continue to help understand GWAS hits. 14/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
However, because we find this substantial enrichment at higher resolutions, we believe effector gene dysregulation is largely contextually restricted. Such effects may therefore hide from selective pressures, and persist at the common frequencies often found by GWAS. 13/
110
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
🤔 We think this makes a lot of sense evolutionarily: If disease effector gene dysregulation is widespread (i.e more detectable at lower resolutions), it may yield a greater phenotypic effect, and be influenced by greater selective pressures. 12/
110
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
So are those effects found at each resolution equally likely to drive disease❓ NO - Those eGenes found at the cell-type level were SUBSTANTIALLY enriched for disease effector genes - a whopping ~3.5-fold (2.68/0.75) more so than the ‘All Cells’ level. 11/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
To see which of these underpin susceptibility, we colocalised these with IBD GWAS. Remarkably, we nominate effector genes at an enormous 74 (❗) loci where one has not previously been nominated in @OpenTargets. This therefore SUBSTANTIALLY improves on previous efforts. 10/
101
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
Something really cool! 🌟 While most genes have an eQTL at the ‘All Cells’ level (‘eGenes’), many eQTLs were found only at higher resolutions. So while rarely finding new eGenes, we find many new regulators. These are further from the TSS and more likely found in enhancers. 9/
120
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
🗺️ We then mapped eQTLs at several resolutions; 1) ‘All Cells’ (like bulk) 2) Major populations (coarse resolution) 3) Cell-types (high resolution) Doing this within or across anatomical sites, we find >84k eQTLs (❗) in 251 different annotations. 8/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
To answer this, we generated ‘IBDverse’ 💫 - The world’s LARGEST collection of scRNAseq data from the sites most relevant for IBD! 🤯 Across this gigantic set of 2.2M cells from 732 samples, we identified 9 major populations that comprised 86 cell-types. 7/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
Using inflammatory bowel disease (IBD) as an example, we wanted to test: 🔍 What kind of eQTLs can we identify if we preserve the cellular resolution of expression by using single-cell RNAseq (sc-eQTLs)? ❓Do these better nominate disease effector genes. 6/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
😥 Unfortunately these have had little success. Most work, however, relies on bulk RNAseq, which requires homogenising a sample much like you do to fruit in a smoothie. But what if disease-causing gene dysregulation is missed by doing this? 5/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
⏩ This led to widespread efforts to identify regulatory variants, a.k.a ‘expression quantitative trait loci’ (eQTLs), that colocalise with GWAS signals, in the hope of pinpointing the effector genes, tissues and cell-types. 4/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
However, ~90% of GWAS hits lie outside genes themselves. While this makes it difficult to nominate the ‘effector gene’, it indicates these likely act by modifying their expression level - this can be quantified by measuring the abundance of the associated RNA. 3/
110
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
🕵️Genome wide association studies (GWAS) seek to identify genetic variants that drive complex traits and diseases. Because we can be fairly confident these variants are causal of the phenotype, drugs targeting associated genes are much more likely to be successful. 2/
100
Bradley Harris @bradleyomics.bsky.social · 08/07/2025
Delighted to share the first preprint of my postdoc in the @carlanderson.bsky.social lab www.medrxiv.org/content/10.1...! 🚨 A super exciting study I co-led with the very talented @tobioinformatics.bsky.social . Stay tuned to see what we learned about genetic susceptibility to complex disease. 🧬🧵 1/
medrxiv.org
Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk
Most genetic variants associated with complex diseases lie in non-coding regions, complicating efforts to identify effector genes and relevant cell types. Here, we map cis-eQTLs across 2.2 million sin...
1207
Reposted by Bradley Harris
Open Targets @opentargets.org · 26/06/2025
Preprint out today! A team led by @tobioinformatics.bsky.social and Bradley Harris in @carlanderson.bsky.social ‘s lab has created the largest single-cell atlas of IBD tissues to date www.medrxiv.org/content/10.1...
UMAP of the 9 populations and 86 cell types identified after quality control and clustering
1197
Bradley Harris @bradleyomics.bsky.social · 26/11/2024
I never caught one this nice though!
000